Skip to Main Content

News & Events

Noteworthy Work

Share via LinkedIn
Share via Twitter
Share via Facebook
Print This Page

K&L Gates Advises StemCyte on US$14 Million IPO on Taiwan Stock Exchange

18 June 2026

Global law firm K&L Gates advised StemCyte International, Ltd. on its US$14 million initial public offering and primary listing on the Taiwan Stock Exchange. The capital raise was completed through the issuance of 22.23 million new shares. 

Established in 2013, StemCyte International, Ltd. is a leading provider of cord blood banking and stem cell-related services, supporting medical research and therapeutic applications worldwide. 

The Corporate team advising StemCyte on the listing was led by Taipei partners Cheryl Hsieh and Billy Chen, with support from Palo Alto partner Kevin Cao.

K&L Gates is a globally integrated law firm trusted by sophisticated clients to deliver market leading legal counsel across jurisdictions and industries. Operating as one firm worldwide, K&L Gates combines deep local insight with seamless global coordination to address clients’ most complex legal and business challenges. Guided by a relentless focus on client service, the firm delivers practical, high impact solutions with consistency, efficiency, and a clear emphasis on results.

Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel